All the latest Form happenings. Want to stay in the loop? Subscribe Now
In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Claire Aldridge, Chief Strategy Officer at Form Bio.
Form Bio’s Chief Strategy Officer, Claire Aldridge, is harnessing the new company’s computing power and bioinformatics to spur a genomic revolution.
New integration delivers 52% cost savings and 88% time savings in computational execution with gpu-accelerated industry-standard tools.
Innovative cell and gene therapies can potentially treat and cure some of the most debilitating diseases known to humankind. But moving preclinical candidates through development, manufacturing and regulatory approval presents some distinct difficulties compared to traditional drug development.
Spinout of George Church’s Colossal Biosciences launches with a ‘sweet spot’ for synthetic biology companies pursuing manufacturing, validation
Jill Roughan, PhD
February 7, 2023
Since their discovery, CRISPR-Cas systems have changed and evolved. Read about how base, prime, and RNA editing are driving new therapeutic applications.
February 1, 2023
As gene therapy becomes more prevalent, so too do the challenges associated with ensuring its safety. Learn how to manufacture the purest and most potent AAV based gene therapy.
Nick Ketz, PhD
January 31, 2023
DeepMind researchers released a large language model (LLM) that uses fewer parameters yet achieves better performance. Read more to understand how this is relevant to your gene therapy programs.
